Cargando…

Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort

Background and objectives: Chronic obstructive pulmonary disease (COPD) is usually comorbid with other chronic diseases. We aimed to assess the multimorbidity medication patterns and explore if the patterns are similar for phase 1 (P1) and 5-year follow-up phase 2 (P2) in the COPDGene cohort. Materi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yisha, Schmiege, Sarah J., Anderson, Heather, Richmond, Nicole E., Young, Kendra A., Hokanson, John E., Rennard, Stephen I., Crume, Tessa L., Austin, Erin, Pratte, Katherine A., Conway, Rebecca, Kinney, Gregory L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221198/
https://www.ncbi.nlm.nih.gov/pubmed/37241208
http://dx.doi.org/10.3390/medicina59050976
_version_ 1785049398960455680
author Li, Yisha
Schmiege, Sarah J.
Anderson, Heather
Richmond, Nicole E.
Young, Kendra A.
Hokanson, John E.
Rennard, Stephen I.
Crume, Tessa L.
Austin, Erin
Pratte, Katherine A.
Conway, Rebecca
Kinney, Gregory L.
author_facet Li, Yisha
Schmiege, Sarah J.
Anderson, Heather
Richmond, Nicole E.
Young, Kendra A.
Hokanson, John E.
Rennard, Stephen I.
Crume, Tessa L.
Austin, Erin
Pratte, Katherine A.
Conway, Rebecca
Kinney, Gregory L.
author_sort Li, Yisha
collection PubMed
description Background and objectives: Chronic obstructive pulmonary disease (COPD) is usually comorbid with other chronic diseases. We aimed to assess the multimorbidity medication patterns and explore if the patterns are similar for phase 1 (P1) and 5-year follow-up phase 2 (P2) in the COPDGene cohort. Materials and Methods: A total of 5564 out of 10,198 smokers from the COPDGene cohort who completed 2 visits, P1 and P2 visits, with complete medication use history were included in the study. We conducted latent class analysis (LCA) among the 27 categories of chronic disease medications, excluding COPD treatments and cancer medications at P1 and P2 separately. The best number of LCA classes was determined through both statistical fit and interpretation of the patterns. Results: We found four classes of medication patterns at both phases. LCA showed that both phases shared similar characteristics in their medication patterns: LC0: low medication; LC1: hypertension (HTN) or cardiovascular disease (CVD)+high cholesterol (Hychol) medication predominant; LC2: HTN/CVD+type 2 diabetes (T2D) +Hychol medication predominant; LC3: Hychol medication predominant. Conclusions: We found similar multimorbidity medication patterns among smokers at P1 and P2 in the COPDGene cohort, which provides an understanding of how multimorbidity medication clustered and how different chronic diseases combine in smokers.
format Online
Article
Text
id pubmed-10221198
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102211982023-05-28 Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort Li, Yisha Schmiege, Sarah J. Anderson, Heather Richmond, Nicole E. Young, Kendra A. Hokanson, John E. Rennard, Stephen I. Crume, Tessa L. Austin, Erin Pratte, Katherine A. Conway, Rebecca Kinney, Gregory L. Medicina (Kaunas) Article Background and objectives: Chronic obstructive pulmonary disease (COPD) is usually comorbid with other chronic diseases. We aimed to assess the multimorbidity medication patterns and explore if the patterns are similar for phase 1 (P1) and 5-year follow-up phase 2 (P2) in the COPDGene cohort. Materials and Methods: A total of 5564 out of 10,198 smokers from the COPDGene cohort who completed 2 visits, P1 and P2 visits, with complete medication use history were included in the study. We conducted latent class analysis (LCA) among the 27 categories of chronic disease medications, excluding COPD treatments and cancer medications at P1 and P2 separately. The best number of LCA classes was determined through both statistical fit and interpretation of the patterns. Results: We found four classes of medication patterns at both phases. LCA showed that both phases shared similar characteristics in their medication patterns: LC0: low medication; LC1: hypertension (HTN) or cardiovascular disease (CVD)+high cholesterol (Hychol) medication predominant; LC2: HTN/CVD+type 2 diabetes (T2D) +Hychol medication predominant; LC3: Hychol medication predominant. Conclusions: We found similar multimorbidity medication patterns among smokers at P1 and P2 in the COPDGene cohort, which provides an understanding of how multimorbidity medication clustered and how different chronic diseases combine in smokers. MDPI 2023-05-18 /pmc/articles/PMC10221198/ /pubmed/37241208 http://dx.doi.org/10.3390/medicina59050976 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Yisha
Schmiege, Sarah J.
Anderson, Heather
Richmond, Nicole E.
Young, Kendra A.
Hokanson, John E.
Rennard, Stephen I.
Crume, Tessa L.
Austin, Erin
Pratte, Katherine A.
Conway, Rebecca
Kinney, Gregory L.
Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort
title Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort
title_full Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort
title_fullStr Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort
title_full_unstemmed Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort
title_short Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort
title_sort longitudinal assessment of multimorbidity medication patterns among smokers in the copdgene cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221198/
https://www.ncbi.nlm.nih.gov/pubmed/37241208
http://dx.doi.org/10.3390/medicina59050976
work_keys_str_mv AT liyisha longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT schmiegesarahj longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT andersonheather longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT richmondnicolee longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT youngkendraa longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT hokansonjohne longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT rennardstepheni longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT crumetessal longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT austinerin longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT prattekatherinea longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT conwayrebecca longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort
AT kinneygregoryl longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort